Click for best price
Biosimilars Market Size, Share 2022
Market Analysis and Insights: Global Biosimilars Market
The global Biosimilars market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Biosimilars market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Biosimilars market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Biosimilars market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Biosimilars market.
Global Biosimilars Scope and Market Size
Biosimilars market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Biosimilars market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
Recombinant Glycosylated Proteins
Segment by Application
Oncology
Blood Disorders
Growth Hormonal Deficiency
Chronic and Autoimmune Disorders
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Pfizer
Novartis
Biocon
Biogen
Fresenius Kabi AG
Boehringer Ingelheim
Merck KgaA
Mylan
Eli Lilly
Teva Pharmaceutical
Dr. Reddy's Laboratories
Amgen
Celltrion
Samsung Biologics
Roche
Probiomed
Apotex
Chong Kun Dang
JCR Pharmaceuticals
Gan & Lee Pharmaceuticals
Gedeon Richter
Biocad
Coherus Bioscience
Stada Arzneimittel AG
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes Biosimilars product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of Biosimilars, with price, sales, revenue, and global market share of Biosimilars from 2019 to 2022.
Chapter 3, the Biosimilars competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Biosimilars breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Biosimilars market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Biosimilars.
Chapter 13, 14, and 15, to describe Biosimilars sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 Biosimilars Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global and United States Biosimilars Market Report & Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
128 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Study Coverage
1.1 Biosimilars Product Introduction
1.2 Global Biosimilars Outlook 2017 VS 2022 VS 2028
1.2.1 Global Biosimilars Sales in US$ Million for the Year 2017-2028
1.2.2 Global Biosimilars Sales in Volume for the Year 2017-2028
1.3 United States Biosimilars Outlook 2017 VS 2022 VS 2028
1.3.1 United States Biosimilars Sales in US$ Million for the Year 2017-2028
1.3.2 United States Biosimilars Sales in Volume for the Year 2017-2028
1.4 Biosimilars Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Biosimilars in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Biosimilars Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Biosimilars Market Dynamics
1.5.1 Biosimilars Industry Trends
1.5.2 Biosimilars Market Drivers
1.5.3 Biosimilars Market Challenges
1.5.4 Biosimilars Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Biosimilars Market Segment by Type
2.1.1 Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
2.1.2 Recombinant Glycosylated Proteins
2.2 Global Biosimilars Market Size by Type
2.2.1 Global Biosimilars Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Biosimilars Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Biosimilars Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Biosimilars Market Size by Type
2.3.1 United States Biosimilars Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Biosimilars Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Biosimilars Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Biosimilars Market Segment by Application
3.1.1 Oncology
3.1.2 Blood Disorders
3.1.3 Growth Hormonal Deficiency
3.1.4 Chronic and Autoimmune Disorders
3.1.5 Others
3.2 Global Biosimilars Market Size by Application
3.2.1 Global Biosimilars Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Biosimilars Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Biosimilars Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Biosimilars Market Size by Application
3.3.1 United States Biosimilars Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Biosimilars Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Biosimilars Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Biosimilars Competitor Landscape by Company
4.1 Global Biosimilars Market Size by Company
4.1.1 Top Global Biosimilars Manufacturers Ranked by Revenue (2021)
4.1.2 Global Biosimilars Revenue by Manufacturer (2017-2022)
4.1.3 Global Biosimilars Sales by Manufacturer (2017-2022)
4.1.4 Global Biosimilars Price by Manufacturer (2017-2022)
4.2 Global Biosimilars Concentration Ratio (CR)
4.2.1 Biosimilars Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Biosimilars in 2021
4.2.3 Global Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Biosimilars Manufacturing Base Distribution, Product Type
4.3.1 Global Biosimilars Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Biosimilars Product Type
4.3.3 Date of International Manufacturers Enter into Biosimilars Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Biosimilars Market Size by Company
4.5.1 Top Biosimilars Players in United States, Ranked by Revenue (2021)
4.5.2 United States Biosimilars Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Biosimilars Sales by Players (2020, 2021 & 2022)
5 Global Biosimilars Market Size by Region
5.1 Global Biosimilars Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Biosimilars Market Size in Volume by Region (2017-2028)
5.2.1 Global Biosimilars Sales in Volume by Region: 2017-2022
5.2.2 Global Biosimilars Sales in Volume Forecast by Region (2023-2028)
5.3 Global Biosimilars Market Size in Value by Region (2017-2028)
5.3.1 Global Biosimilars Sales in Value by Region: 2017-2022
5.3.2 Global Biosimilars Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Biosimilars Market Size YoY Growth 2017-2028
6.1.2 North America Biosimilars Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Biosimilars Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Biosimilars Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 China Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.3 Europe
6.3.1 Europe Biosimilars Market Size YoY Growth 2017-2028
6.3.2 Europe Biosimilars Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Biosimilars Market Size YoY Growth 2017-2028
6.4.2 Latin America Biosimilars Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Biosimilars Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Biosimilars Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Corporation Information
7.1.2 Pfizer Description and Business Overview
7.1.3 Pfizer Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Pfizer Biosimilars Products Offered
7.1.5 Pfizer Recent Development
7.2 Novartis
7.2.1 Novartis Corporation Information
7.2.2 Novartis Description and Business Overview
7.2.3 Novartis Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Novartis Biosimilars Products Offered
7.2.5 Novartis Recent Development
7.3 Biocon
7.3.1 Biocon Corporation Information
7.3.2 Biocon Description and Business Overview
7.3.3 Biocon Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Biocon Biosimilars Products Offered
7.3.5 Biocon Recent Development
7.4 Biogen
7.4.1 Biogen Corporation Information
7.4.2 Biogen Description and Business Overview
7.4.3 Biogen Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Biogen Biosimilars Products Offered
7.4.5 Biogen Recent Development
7.5 Fresenius Kabi AG
7.5.1 Fresenius Kabi AG Corporation Information
7.5.2 Fresenius Kabi AG Description and Business Overview
7.5.3 Fresenius Kabi AG Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Fresenius Kabi AG Biosimilars Products Offered
7.5.5 Fresenius Kabi AG Recent Development
7.6 Boehringer Ingelheim
7.6.1 Boehringer Ingelheim Corporation Information
7.6.2 Boehringer Ingelheim Description and Business Overview
7.6.3 Boehringer Ingelheim Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Boehringer Ingelheim Biosimilars Products Offered
7.6.5 Boehringer Ingelheim Recent Development
7.7 Merck KgaA
7.7.1 Merck KgaA Corporation Information
7.7.2 Merck KgaA Description and Business Overview
7.7.3 Merck KgaA Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Merck KgaA Biosimilars Products Offered
7.7.5 Merck KgaA Recent Development
7.8 Mylan
7.8.1 Mylan Corporation Information
7.8.2 Mylan Description and Business Overview
7.8.3 Mylan Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Mylan Biosimilars Products Offered
7.8.5 Mylan Recent Development
7.9 Eli Lilly
7.9.1 Eli Lilly Corporation Information
7.9.2 Eli Lilly Description and Business Overview
7.9.3 Eli Lilly Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Eli Lilly Biosimilars Products Offered
7.9.5 Eli Lilly Recent Development
7.10 Teva Pharmaceutical
7.10.1 Teva Pharmaceutical Corporation Information
7.10.2 Teva Pharmaceutical Description and Business Overview
7.10.3 Teva Pharmaceutical Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Teva Pharmaceutical Biosimilars Products Offered
7.10.5 Teva Pharmaceutical Recent Development
7.11 Dr. Reddy's Laboratories
7.11.1 Dr. Reddy's Laboratories Corporation Information
7.11.2 Dr. Reddy's Laboratories Description and Business Overview
7.11.3 Dr. Reddy's Laboratories Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Dr. Reddy's Laboratories Biosimilars Products Offered
7.11.5 Dr. Reddy's Laboratories Recent Development
7.12 Amgen
7.12.1 Amgen Corporation Information
7.12.2 Amgen Description and Business Overview
7.12.3 Amgen Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Amgen Products Offered
7.12.5 Amgen Recent Development
7.13 Celltrion
7.13.1 Celltrion Corporation Information
7.13.2 Celltrion Description and Business Overview
7.13.3 Celltrion Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Celltrion Products Offered
7.13.5 Celltrion Recent Development
7.14 Samsung Biologics
7.14.1 Samsung Biologics Corporation Information
7.14.2 Samsung Biologics Description and Business Overview
7.14.3 Samsung Biologics Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Samsung Biologics Products Offered
7.14.5 Samsung Biologics Recent Development
7.15 Roche
7.15.1 Roche Corporation Information
7.15.2 Roche Description and Business Overview
7.15.3 Roche Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Roche Products Offered
7.15.5 Roche Recent Development
7.16 Probiomed
7.16.1 Probiomed Corporation Information
7.16.2 Probiomed Description and Business Overview
7.16.3 Probiomed Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.16.4 Probiomed Products Offered
7.16.5 Probiomed Recent Development
7.17 Apotex
7.17.1 Apotex Corporation Information
7.17.2 Apotex Description and Business Overview
7.17.3 Apotex Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.17.4 Apotex Products Offered
7.17.5 Apotex Recent Development
7.18 Chong Kun Dang
7.18.1 Chong Kun Dang Corporation Information
7.18.2 Chong Kun Dang Description and Business Overview
7.18.3 Chong Kun Dang Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.18.4 Chong Kun Dang Products Offered
7.18.5 Chong Kun Dang Recent Development
7.19 JCR Pharmaceuticals
7.19.1 JCR Pharmaceuticals Corporation Information
7.19.2 JCR Pharmaceuticals Description and Business Overview
7.19.3 JCR Pharmaceuticals Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.19.4 JCR Pharmaceuticals Products Offered
7.19.5 JCR Pharmaceuticals Recent Development
7.20 Gan & Lee Pharmaceuticals
7.20.1 Gan & Lee Pharmaceuticals Corporation Information
7.20.2 Gan & Lee Pharmaceuticals Description and Business Overview
7.20.3 Gan & Lee Pharmaceuticals Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.20.4 Gan & Lee Pharmaceuticals Products Offered
7.20.5 Gan & Lee Pharmaceuticals Recent Development
7.21 Gedeon Richter
7.21.1 Gedeon Richter Corporation Information
7.21.2 Gedeon Richter Description and Business Overview
7.21.3 Gedeon Richter Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.21.4 Gedeon Richter Products Offered
7.21.5 Gedeon Richter Recent Development
7.22 Biocad
7.22.1 Biocad Corporation Information
7.22.2 Biocad Description and Business Overview
7.22.3 Biocad Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.22.4 Biocad Products Offered
7.22.5 Biocad Recent Development
7.23 Coherus Bioscience
7.23.1 Coherus Bioscience Corporation Information
7.23.2 Coherus Bioscience Description and Business Overview
7.23.3 Coherus Bioscience Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.23.4 Coherus Bioscience Products Offered
7.23.5 Coherus Bioscience Recent Development
7.24 Stada Arzneimittel AG
7.24.1 Stada Arzneimittel AG Corporation Information
7.24.2 Stada Arzneimittel AG Description and Business Overview
7.24.3 Stada Arzneimittel AG Biosimilars Sales, Revenue and Gross Margin (2017-2022)
7.24.4 Stada Arzneimittel AG Products Offered
7.24.5 Stada Arzneimittel AG Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Biosimilars Industry Chain Analysis
8.2 Biosimilars Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Biosimilars Distributors
8.3 Biosimilars Production Mode & Process
8.4 Biosimilars Sales and Marketing
8.4.1 Biosimilars Sales Channels
8.4.2 Biosimilars Distributors
8.5 Biosimilars Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Biosimilars CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Biosimilars Market Trends
Table 3. Biosimilars Market Drivers
Table 4. Biosimilars Market Challenges
Table 5. Biosimilars Market Restraints
Table 6. Global Biosimilars Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Biosimilars Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Biosimilars Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Biosimilars Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Biosimilars Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Biosimilars Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Biosimilars Revenue Share by Manufacturer, 2017-2022
Table 13. Global Biosimilars Sales by Manufacturer, (K MT), 2017-2022
Table 14. Global Biosimilars Sales Share by Manufacturer, 2017-2022
Table 15. Global Biosimilars Price by Manufacturer (2017-2022) & (USD/MT)
Table 16. Global Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilars as of 2021)
Table 18. Top Players of Biosimilars in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Biosimilars Product Type
Table 20. Date of International Manufacturers Enter into Biosimilars Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Biosimilars Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Biosimilars Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Biosimilars Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Biosimilars Sales by Players, (K MT), 2020, 2021 & 2022
Table 26. United States Biosimilars Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Biosimilars Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Biosimilars Sales in Volume by Region (2017-2022) & (K MT)
Table 29. Global Biosimilars Sales in Volume Forecast by Region (2023-2028) & (K MT)
Table 30. Global Biosimilars Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Biosimilars Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Biosimilars Sales in Volume by Country (2017-2028) & (K MT)
Table 33. North America Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Biosimilars Sales in Volume by Region (2017-2028) & (K MT)
Table 35. Asia Pacific Biosimilars Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Biosimilars Sales in Volume by Country (2017-2028) & (K MT)
Table 37. Europe Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Biosimilars Sales in Volume by Country (2017-2028) & (K MT)
Table 39. Latin Americaa Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Biosimilars Sales in Volume by Country (2017-2028) & (K MT)
Table 41. Middle East and Africa Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Pfizer Corporation Information
Table 43. Pfizer Description and Business Overview
Table 44. Pfizer Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 45. Pfizer Biosimilars Product
Table 46. Pfizer Recent Development
Table 47. Novartis Corporation Information
Table 48. Novartis Description and Business Overview
Table 49. Novartis Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 50. Novartis Product
Table 51. Novartis Recent Development
Table 52. Biocon Corporation Information
Table 53. Biocon Description and Business Overview
Table 54. Biocon Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 55. Biocon Product
Table 56. Biocon Recent Development
Table 57. Biogen Corporation Information
Table 58. Biogen Description and Business Overview
Table 59. Biogen Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 60. Biogen Product
Table 61. Biogen Recent Development
Table 62. Fresenius Kabi AG Corporation Information
Table 63. Fresenius Kabi AG Description and Business Overview
Table 64. Fresenius Kabi AG Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 65. Fresenius Kabi AG Product
Table 66. Fresenius Kabi AG Recent Development
Table 67. Boehringer Ingelheim Corporation Information
Table 68. Boehringer Ingelheim Description and Business Overview
Table 69. Boehringer Ingelheim Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 70. Boehringer Ingelheim Product
Table 71. Boehringer Ingelheim Recent Development
Table 72. Merck KgaA Corporation Information
Table 73. Merck KgaA Description and Business Overview
Table 74. Merck KgaA Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 75. Merck KgaA Product
Table 76. Merck KgaA Recent Development
Table 77. Mylan Corporation Information
Table 78. Mylan Description and Business Overview
Table 79. Mylan Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 80. Mylan Product
Table 81. Mylan Recent Development
Table 82. Eli Lilly Corporation Information
Table 83. Eli Lilly Description and Business Overview
Table 84. Eli Lilly Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 85. Eli Lilly Product
Table 86. Eli Lilly Recent Development
Table 87. Teva Pharmaceutical Corporation Information
Table 88. Teva Pharmaceutical Description and Business Overview
Table 89. Teva Pharmaceutical Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 90. Teva Pharmaceutical Product
Table 91. Teva Pharmaceutical Recent Development
Table 92. Dr. Reddy's Laboratories Corporation Information
Table 93. Dr. Reddy's Laboratories Description and Business Overview
Table 94. Dr. Reddy's Laboratories Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 95. Dr. Reddy's Laboratories Product
Table 96. Dr. Reddy's Laboratories Recent Development
Table 97. Amgen Corporation Information
Table 98. Amgen Description and Business Overview
Table 99. Amgen Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 100. Amgen Product
Table 101. Amgen Recent Development
Table 102. Celltrion Corporation Information
Table 103. Celltrion Description and Business Overview
Table 104. Celltrion Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 105. Celltrion Product
Table 106. Celltrion Recent Development
Table 107. Samsung Biologics Corporation Information
Table 108. Samsung Biologics Description and Business Overview
Table 109. Samsung Biologics Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 110. Samsung Biologics Product
Table 111. Samsung Biologics Recent Development
Table 112. Roche Corporation Information
Table 113. Roche Description and Business Overview
Table 114. Roche Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 115. Roche Product
Table 116. Roche Recent Development
Table 117. Probiomed Corporation Information
Table 118. Probiomed Description and Business Overview
Table 119. Probiomed Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 120. Probiomed Product
Table 121. Probiomed Recent Development
Table 122. Apotex Corporation Information
Table 123. Apotex Description and Business Overview
Table 124. Apotex Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 125. Apotex Product
Table 126. Apotex Recent Development
Table 127. Chong Kun Dang Corporation Information
Table 128. Chong Kun Dang Description and Business Overview
Table 129. Chong Kun Dang Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 130. Chong Kun Dang Product
Table 131. Chong Kun Dang Recent Development
Table 132. JCR Pharmaceuticals Corporation Information
Table 133. JCR Pharmaceuticals Description and Business Overview
Table 134. JCR Pharmaceuticals Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 135. JCR Pharmaceuticals Product
Table 136. JCR Pharmaceuticals Recent Development
Table 137. Gan & Lee Pharmaceuticals Corporation Information
Table 138. Gan & Lee Pharmaceuticals Description and Business Overview
Table 139. Gan & Lee Pharmaceuticals Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 140. Gan & Lee Pharmaceuticals Product
Table 141. Gan & Lee Pharmaceuticals Recent Development
Table 142. Gedeon Richter Corporation Information
Table 143. Gedeon Richter Description and Business Overview
Table 144. Gedeon Richter Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 145. Gedeon Richter Product
Table 146. Gedeon Richter Recent Development
Table 147. Biocad Corporation Information
Table 148. Biocad Description and Business Overview
Table 149. Biocad Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 150. Biocad Product
Table 151. Biocad Recent Development
Table 152. Coherus Bioscience Corporation Information
Table 153. Coherus Bioscience Description and Business Overview
Table 154. Coherus Bioscience Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 155. Coherus Bioscience Product
Table 156. Coherus Bioscience Recent Development
Table 157. Stada Arzneimittel AG Corporation Information
Table 158. Stada Arzneimittel AG Description and Business Overview
Table 159. Stada Arzneimittel AG Biosimilars Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 160. Stada Arzneimittel AG Product
Table 161. Stada Arzneimittel AG Recent Development
Table 162. Key Raw Materials Lists
Table 163. Raw Materials Key Suppliers Lists
Table 164. Biosimilars Customers List
Table 165. Biosimilars Distributors List
Table 166. Research Programs/Design for This Report
Table 167. Key Data Information from Secondary Sources
Table 168. Key Data Information from Primary Sources
List of Figures
Figure 1. Biosimilars Product Picture
Figure 2. Global Biosimilars Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Biosimilars Market Size 2017-2028 (US$ Million)
Figure 4. Global Biosimilars Sales 2017-2028 (K MT)
Figure 5. United States Biosimilars Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Biosimilars Market Size 2017-2028 (US$ Million)
Figure 7. United States Biosimilars Sales 2017-2028 (K MT)
Figure 8. United States Biosimilars Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Biosimilars Market Share in Global, in Volume (K MT) 2017-2028
Figure 10. Biosimilars Report Years Considered
Figure 11. Product Picture of Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
Figure 12. Product Picture of Recombinant Glycosylated Proteins
Figure 13. Global Biosimilars Market Share by Type in 2022 & 2028
Figure 14. Global Biosimilars Sales in Value by Type (2017-2028) & (US$ Million)
Figure 15. Global Biosimilars Sales Market Share in Value by Type (2017-2028)
Figure 16. Global Biosimilars Sales by Type (2017-2028) & (K MT)
Figure 17. Global Biosimilars Sales Market Share in Volume by Type (2017-2028)
Figure 18. Global Biosimilars Price by Type (2017-2028) & (USD/MT)
Figure 19. United States Biosimilars Market Share by Type in 2022 & 2028
Figure 20. United States Biosimilars Sales in Value by Type (2017-2028) & (US$ Million)
Figure 21. United States Biosimilars Sales Market Share in Value by Type (2017-2028)
Figure 22. United States Biosimilars Sales by Type (2017-2028) & (K MT)
Figure 23. United States Biosimilars Sales Market Share in Volume by Type (2017-2028)
Figure 24. United States Biosimilars Price by Type (2017-2028) & (USD/MT)
Figure 25. Product Picture of Oncology
Figure 26. Product Picture of Blood Disorders
Figure 27. Product Picture of Growth Hormonal Deficiency
Figure 28. Product Picture of Chronic and Autoimmune Disorders
Figure 29. Product Picture of Others
Figure 30. Global Biosimilars Market Share by Application in 2022 & 2028
Figure 31. Global Biosimilars Sales in Value by Application (2017-2028) & (US$ Million)
Figure 32. Global Biosimilars Sales Market Share in Value by Application (2017-2028)
Figure 33. Global Biosimilars Sales by Application (2017-2028) & (K MT)
Figure 34. Global Biosimilars Sales Market Share in Volume by Application (2017-2028)
Figure 35. Global Biosimilars Price by Application (2017-2028) & (USD/MT)
Figure 36. United States Biosimilars Market Share by Application in 2022 & 2028
Figure 37. United States Biosimilars Sales in Value by Application (2017-2028) & (US$ Million)
Figure 38. United States Biosimilars Sales Market Share in Value by Application (2017-2028)
Figure 39. United States Biosimilars Sales by Application (2017-2028) & (K MT)
Figure 40. United States Biosimilars Sales Market Share in Volume by Application (2017-2028)
Figure 41. United States Biosimilars Price by Application (2017-2028) & (USD/MT)
Figure 42. North America Biosimilars Sales in Volume Growth Rate 2017-2028 (K MT)
Figure 43. North America Biosimilars Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 44. U.S. Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 45. Canada Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 46. Europe Biosimilars Sales in Volume Growth Rate 2017-2028 (K MT)
Figure 47. Europe Biosimilars Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 48. Germany Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 49. France Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 50. U.K. Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 51. Italy Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 52. Russia Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 53. Asia-Pacific Biosimilars Sales in Volume Growth Rate 2017-2028 (K MT)
Figure 54. Asia-Pacific Biosimilars Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 55. China Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 56. Japan Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. South Korea Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. India Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. Australia Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. China Taiwan Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Indonesia Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Thailand Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 63. Malaysia Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 64. Latin America Biosimilars Sales in Volume Growth Rate 2017-2028 (K MT)
Figure 65. Latin America Biosimilars Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 66. Mexico Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 67. Brazil Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 68. Argentina Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 69. Middle East & Africa Biosimilars Sales in Volume Growth Rate 2017-2028 (K MT)
Figure 70. Middle East & Africa Biosimilars Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 71. Turkey Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 72. Saudi Arabia Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 73. UAE Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 74. Biosimilars Value Chain
Figure 75. Biosimilars Production Process
Figure 76. Channels of Distribution
Figure 77. Distributors Profiles
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed
